Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Many PIM inhibitors have been reported
2020-06-11

Many PIM inhibitors have been reported to date [7], [8], [9] however, none of them has been marketed so far. SGI-1776 is a representative first-generation PIM inhibitor, which had been under clinical trials for leukemia and prostate cancer [10]. While most of the first-generation PIM inhibitors are
-
The present study failed to demonstrate an
2020-06-11

The present study failed to demonstrate an independent association of preoperative ChE with BCR. This is in contrast to Koie et al. who reported that pretreatment serum ChE was significantly associated with BCR in 535 patients with CaP who underwent RP (5-year BRFS rates were 77.7% and 55.0%, respec
-
NSC23766 br Experimental protocols br Acknowledgements This
2020-06-11

Experimental protocols Acknowledgements This research was funded by the Croatian Ministry of Science, Education and Sports (Programmes 098-0982915-2948 and 098-0982522-2525), the Austrian Science Fund FWF (DK-MCD W1226, SFB LIPOTOX F30, P22832), and the Croatian-Austrian Intergovernmental S&T
-
Several CHK inhibitors have been reported in the
2020-06-11

Several CHK-1 inhibitors have been reported in the literature. Of these, UCN-01 (7-hydroxystaurosporine) is a potent inhibitor of CHK-1 (=5.6nM), , and has modest selectivity among other kinases. UCN-01 is currently in clinical trials. Other CHK-1 inhibitors reported in the literature include indaz
-
Compounds were synthesized as illustrated in tetrazole
2020-06-11

Compounds – were synthesized as illustrated in , , , , . 3-(1-tetrazole-5-yl)benzaldehyde was obtained in 95% yield via [2+3] cycloaddition of sodium azide to commercially available 3-cyanobenzaldehyde in presence of triethylamine as reported in the literature. Nitration of 3-hydroxyacetophenone wi
-
Even minor alterations in the surfactants structure could ha
2020-06-11

Even minor alterations in the surfactants structure could have consequences on their physico-chemical characteristics; mono-RLs have less solubility, stronger surfaces sorb, and stronger cationic metals binding than homologue di-RLs (Zhang et al., 1997). The HPLC separation of RLs structure is base
-
The third challenge is to understand the mechanisms of drug
2020-06-11

The third challenge is to understand the mechanisms of drug resistance. There are several different mechanisms of ES tumor to develop drug resistance. First, cancer stem cells are capable of proliferate and generate tumor cells with new sets of mutations which may harbor different protein targets [1
-
somatostatin agonist In general terms PLA s participate in t
2020-06-11

In general terms, PLA2s participate in the Lands cycle of phospholipid fatty somatostatin agonist recycling [1,15,25], whereby the fatty acid composition at the sn-2 position of phospholipids is tightly controlled by a balance between hydrolytic reactions mediated by PLA2s versus activation of the f
-
Simulation methods In our study the TIP P model
2020-06-11

Simulation methods In our study, the TIP3P model is applied for water, AMBER99sb force field [24] is used to describe three types of EGFR, including the wild type (PDB: 2ITY) [25], its mutant G719S (PDB: 2ITO) [25] and mutant T790M (PDB: 3IKA) [26]. The force field of Tubemoside molecule is paramet
-
br Acknowledgments This work was supported
2020-06-11

Acknowledgments This work was supported by Grants from the National Research Foundation (2010-0000782) and the National Center for GM Crops (PJ008152) of the Next Generation BioGreen 21 Program funded by the Rural Development Administration, Republic of Korea, to W.T.K. Introduction Ubiquityl
-
br Multi subunit RINGs There are
2020-06-11

Multi-subunit RINGs There are RING-type E3s that exist as multi-subunit assemblies (see Fig. 3B). A striking example is the Cullin RING Ligase (CRL) superfamily [35], which exhibits enormous plasticity in substrate specificity. Each CRL subfamily is characterized by a cullin protein (Cul-1, 2, 3,
-
br Substoichiometric substrate modification E ligases cataly
2020-06-11

Substoichiometric substrate modification E3 ligases catalyze the rapid transfer of the SUMOD from the E2 enzyme to the substrate. By definition, enzymes are recycled in the reaction, allowing multiple rounds of substrate modification by a single enzyme. Thus, enzymes function at substoichiometric
-
Analysis of Table shows that compound b
2020-06-11

Analysis of Table 1 shows that compound 7b, in which the biphenyl scaffold does not bear any substituent, displays its inhibitory potency in the micromolar range (IC50 = 11 μM). If the amide bridge is moved from position 1 to 3 of the biphenyl system, product 7c is yielded, whose potency is about 4
-
br Methods br Results and discussion br Acknowledgements br
2020-06-11

Methods Results and discussion Acknowledgements Introduction Diacylglycerol O-acyltransferase (DGAT) is a key enzyme that catalyzes the final committed step in triglyceride synthesis and is highly expressed in the small intestine, adipose tissue, liver and mammary gland.1, 2, 3, 4 Its im
-
The present study manipulated dopaminergic functioning by ex
2020-06-10

The present study “manipulated” dopaminergic functioning by examining genetic variation related to the catechol-O-methyltransferase (COMT) gene. The gene transcribes the COMT enzyme involved in degradation of released dopamine in the frontal cortex. COMT is primarily localized to the frontal cortex
13485 records 681/899 page Previous Next First page 上5页 681682683684685 下5页 Last page